142 related articles for article (PubMed ID: 31465840)
41. The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo.
Gonnissen A; Isebaert S; McKee CM; Dok R; Haustermans K; Muschel RJ
Oncotarget; 2016 Dec; 7(51):84286-84298. PubMed ID: 27713179
[TBL] [Abstract][Full Text] [Related]
42. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.
Arnhold V; Boos J; Lanvers-Kaminsky C
Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311
[TBL] [Abstract][Full Text] [Related]
43. Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells.
Hu Q; Hou YC; Huang J; Fang JY; Xiong H
J Exp Clin Cancer Res; 2017 Apr; 36(1):50. PubMed ID: 28399898
[TBL] [Abstract][Full Text] [Related]
44. Chemical, computational and functional insights into the chemical stability of the Hedgehog pathway inhibitor GANT61.
Calcaterra A; Iovine V; Botta B; Quaglio D; D'Acquarica I; Ciogli A; Iazzetti A; Alfonsi R; Lospinoso Severini L; Infante P; Di Marcotullio L; Mori M; Ghirga F
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):349-358. PubMed ID: 29338454
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
Oladapo HO; Tarpley M; Sauer SJ; Addo KA; Ingram SM; Strepay D; Ehe BK; Chdid L; Trinkler M; Roques JR; Darr DB; Fleming JM; Devi GR; Williams KP
Cancer Lett; 2017 Dec; 411():136-149. PubMed ID: 28965853
[TBL] [Abstract][Full Text] [Related]
46. Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity.
Lau BW; Huh K; Madero-Marroquin R; De Marchi F; Lim Y; Wang Q; Lobo F; Marchionni L; Smith DB; DeZern A; Levis MJ; Aplan PD; Matsui W; Gondek LP
Oncogene; 2019 Jan; 38(5):687-698. PubMed ID: 30171262
[TBL] [Abstract][Full Text] [Related]
47. Hedgehog signaling inhibitor GANT61 induces endoplasmic reticulum stress-mediated protective autophagy in hepatic stellate cells.
Li J; Zhang L; Xia Q; Fu J; Zhou Z; Lin F
Biochem Biophys Res Commun; 2017 Nov; 493(1):487-493. PubMed ID: 28870808
[TBL] [Abstract][Full Text] [Related]
48. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.
Miyazaki Y; Matsubara S; Ding Q; Tsukasa K; Yoshimitsu M; Kosai K; Takao S
Mol Cancer; 2016 Jun; 15(1):49. PubMed ID: 27349387
[TBL] [Abstract][Full Text] [Related]
49. Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.
Dagklis A; Demeyer S; De Bie J; Radaelli E; Pauwels D; Degryse S; Gielen O; Vicente C; Vandepoel R; Geerdens E; Uyttebroeck A; Boeckx N; de Bock CE; Cools J
Blood; 2016 Dec; 128(23):2642-2654. PubMed ID: 27694322
[TBL] [Abstract][Full Text] [Related]
50. Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia.
Bongiovanni D; Tosello V; Saccomani V; Dalla Santa S; Amadori A; Zanovello P; Piovan E
Oncogene; 2020 Oct; 39(42):6544-6555. PubMed ID: 32917954
[TBL] [Abstract][Full Text] [Related]
51. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
52. Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia.
Ghia EM; Rassenti LZ; Neuberg DS; Blanco A; Yousif F; Smith EN; McPherson JD; Hudson TJ; ; Harismendy O; Frazer KA; Kipps TJ
Blood; 2019 Jun; 133(25):2651-2663. PubMed ID: 30923040
[TBL] [Abstract][Full Text] [Related]
53. The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met.
Williamson AJ; Doscas ME; Ye J; Heiden KB; Xing M; Li Y; Prinz RA; Xu X
Oncotarget; 2016 Mar; 7(9):10472-85. PubMed ID: 26859575
[TBL] [Abstract][Full Text] [Related]
54. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Kour S; Rana S; Contreras JI; King HM; Robb CM; Sonawane YA; Bendjennat M; Crawford AJ; Barger CJ; Kizhake S; Luo X; Hollingsworth MA; Natarajan A
Mol Pharmacol; 2019 Oct; 96(4):419-429. PubMed ID: 31467029
[TBL] [Abstract][Full Text] [Related]
55. Unraveling the therapeutic potential of GANT61/Dactolisib combination as a novel prostate cancer modality.
Youssef M; Moussa N; W Helmy M; Haroun M
Med Oncol; 2022 Jul; 39(10):143. PubMed ID: 35834137
[TBL] [Abstract][Full Text] [Related]
56. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
Masetti R; Bertuccio SN; Astolfi A; Chiarini F; Lonetti A; Indio V; De Luca M; Bandini J; Serravalle S; Franzoni M; Pigazzi M; Martelli AM; Basso G; Locatelli F; Pession A
J Hematol Oncol; 2017 Jan; 10(1):26. PubMed ID: 28109323
[TBL] [Abstract][Full Text] [Related]
57. Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.
Erdogdu U; Dolgikh N; Laszig S; Särchen V; Meister MT; Wanior M; Knapp S; Boedicker C
Neoplasia; 2022 Feb; 24(2):109-119. PubMed ID: 34959030
[TBL] [Abstract][Full Text] [Related]
58. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.
Heinicke U; Kupka J; Fulda S
Oncotarget; 2015 Nov; 6(35):37836-51. PubMed ID: 26473375
[TBL] [Abstract][Full Text] [Related]
59. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
60. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
Jokinen E; Koivunen JP
Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
